Investors looking for profitable pandemic plays have a plethora of biotech firms to choose from. The one that’s the subject of today’s article, however, may not be one of them, despite the fact that some are betting on it as a COVID play. In fact, one market analyst has warned “Investors beware” in regards to this stock. For the stock in question and a look at the concerns surrounding it, CLICK HERE.
Goldman Sees This As The More Important Factor For Stocks – And Upside Potential In These 2 Therapeutics Companies
How important a factor is the outcome of the presidential election for the direction of stocks? Not as important as a COVID-19 vaccine, according to Goldman Sachs. With this in mind, today’s article highlights two therapeutics companies focused on battling neurodegenerative diseases where analysts at Goldman see significant upside potential. For these two stocks – both of which have earned “Strong Buy” consensus analyst ratings, CLICK HERE.
9 Biotech Stocks With Key Fourth-Quarter Catalysts
“Biopharma stocks are risky bets that could fetch disproportionate gains or wipe away one’s entire investment thanks to their vulnerability to catalytic events,” acknowledges the author of today’s article before proceeding to identify nine biotech stocks with key catalysts in the final months of 2020. For these nine stocks and their respective fourth-quarter catalysts and price targets, CLICK HERE.
1 Buy, 2 Sells From One Of The Hottest Sectors
As investors attempt to identify the COVID-19 vaccine stock that will beat all the others, biotech has become one of the hottest sectors, with the S&P Biotech SPDR ETF having jumped nearly 80% since hitting its March low. Today’s article offers an analysis of three specific biotech stocks and insights on what to do with each if you are considering buying them or already own them. Which of the three do the contributors believe is a buy, and which two do they recommend selling? CLICK HERE.
The Challenge Of Biotech Investing Before, During And After COVID
“The premise here is simple: biotech investing is just as it was before COVID-19 and as it will be when the pandemic is finally over,” begins the author of today’s article. If one accepts this premise, what does that mean for investing in the three fronts of the war on the coronavirus (testing, treatment and vaccination)? For the author’s overview of each of these three areas – as well as the sole start-up biotech he is invested in right now – CLICK HERE.
Wedbush’s Head Of Healthcare Equity Research Is Bullish On These Genetic-Medicine And Oncology Stocks
Dr. David Nierengarten, Managing Director and Head of Healthcare Equity Research at Wedbush Securities, sees potential in many biotech stocks, especially in the genetic-medicine and oncology spaces. For several specific genetic-medicine and oncology names that Nierengarten is particularly bullish on – including one company with a gene therapy for a rare retinal disease that causes significant vision loss (and sometimes complete blindness) in males – CLICK HERE.
New Biotech Stocks To Watch – And More!
A clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics and a clinical- stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer’s disease and Parkinson’s disease are among seven new biotech stocks to watch highlighted in today’s article, which also highlights new stocks to watch in the tech, defense, and real estate sectors. For these stocks – all of which are Nasdaq/NYSE listed IPOs for September – CLICK HERE.
Missed Out On This Biotech’s 3,600% Surge? Further Gains May Be On The Horizon
The biotech firm highlighted in today’s article, which in the past year has refocused its efforts on a newer cancer-fighting technology, is the No. 4 best-performing stock on the Nasdaq Composite Index and the No. 1 best-performing stock on Canada’s S&P/TSX Composite Index – and despite having already experienced a 3,600% surge, the author notes that “every analyst covering the company rates it a buy, signaling that further gains are on the horizon for investors that missed out on [its] initial boom.” For more on this biotech – which is speculated could be an M&A target – CLICK HERE.
These Biotech Companies Await FDA Decisions In October
There’s perhaps no greater catalyst for shares of a biotech company than FDA approval of one of its product candidates. Conversely, an unfavorable ruling by the FDA can send shares of a biotech firm plummeting. With the FDA having approved 40 novel drugs so far this year (compared to 27 by this same time last year), today’s article takes a look at biotech companies that are expected to receive FDA rulings in October. For more, CLICK HERE.
This Speculative Biotech’s Treatment Candidate For Head And Neck Cancer Gives It Massive Upside Potential
With the global market for head and neck cancer expected to reach $4.5 billion by 2027, the clinical-stage immuno-oncology company highlighted in today’s article – which has entered into a clinical trial collaboration with Merck to treat patients with head and neck squamous cell carcinoma with its lead product candidate – has massive upside potential. For more on this company and why the author believes it’s a good speculative biotech to buy, CLICK HERE.
